<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01226420</url>
  </required_header>
  <id_info>
    <org_study_id>10-230</org_study_id>
    <nct_id>NCT01226420</nct_id>
  </id_info>
  <brief_title>Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host Disease</brief_title>
  <official_title>A Phase II, Open-Label, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Alefacept is a drug tht may reduce the number of T cells in circulation. This drug has been
      used in the treatment of psoriasis, which is a skin disorder also caused by T cells, like
      chronic GVHD. Information from studies in psoriasis and in other patients with GVHD suggests
      that this drug may help to treat chronic GVHD. Chronic GVHD is a medical condition that can
      develop after allogeneic stem cell transplantation. It occurs when the donor immune cells
      (the &quot;graft&quot;) attack and damage organs and tissue (the &quot;host&quot;). It is thought that T cells, a
      subtype of immune cells, are responsible for the tissue damage in chronic GVHD. In this
      research study we are looking to see how well Alefacept works in treating chronic GVHD that
      has not resolved after therapy with corticosteroids.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  During the first week of treatment, participants will receive 2 doses of Alefacept
           intravenously (Day 1 and Day 4). During weeks 2-12, Alefacept will be given
           subcutaneously once weekly.

        -  On weeks 1, 2 and every other week through Week 12 of study treatment, participants will
           have a physical exam, blood tests, and be asked general health and specific questions
           about any problems they may be having.

        -  Every other week, participants will be asked to complete a questionnaire about their
           physical symptoms, activity level and emotional well being.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Discontinuation of drug supply from Astellas.
  </why_stopped>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy</measure>
    <time_frame>2 years</time_frame>
    <description>Proportion of patients with a favorable response, defined as a complete or partial remission at week 12 as compared to baseline in subjects with steroid refractory cGVHD.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of Alefacept Infusions in Patients With Chronic GVHD.</measure>
    <time_frame>2 years</time_frame>
    <description>Assess the safety of alefacept in this patient population. The number of adverse events (including hematological and non-hematological safety events) will be used for safety assessment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Chronic Graft-versus-host Disease</condition>
  <arm_group>
    <arm_group_label>Alefacept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alefacept iv</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alefacept</intervention_name>
    <description>Given intravenously Days 1 and 4 of Week 1, then subcutaneously once weekly for Weeks 2-12</description>
    <arm_group_label>Alefacept</arm_group_label>
    <other_name>Amevive</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older

          -  Diagnosed with cGVHD according to NIH criteria

          -  Active cGVHD despite treatment with corticosteroids AND one additional
             immunosuppressive agent for at least 4 weeks, within 52 weeks of enrollment.

          -  Subject is a recipient of related or unrelated BMT or PBSCT

          -  Subject underwent transplantation at least 6 months prior to enrollment

          -  Subject is on stable immunosuppressive regimen for 2 weeks prior to enrollment.
             Adjustment of immunosuppressive medications to maintain a therapeutic level is
             permitted.

          -  Female of child bearing potential must have a negative pregnancy test prior to first
             dose of alefacept and must agree to practice effective contraception during the study.
             Men must also agree to use adequate contraception prior to study entry and for the
             duration of the study.

          -  Meets medication restriction requirements and agrees to follow medications
             restrictions during study.

        Exclusion Criteria:

          -  Received donor lymphocyte infusions in the preceding 100 days

          -  Currently undergoing ECP

          -  Subject is recipient of related or unrelated UCB

          -  Subject has bronchiolitis obliterans, bronchiolitis obliterans with organizing
             pneumonia or cryptogenic organizing pneumonia as the sole manifestation of cGVHD

          -  Uncontrolled intercurrent active infection.

          -  Absolute neutrophil count &lt; 1000/L

          -  AST, ALT or total bilirubin &gt; 2x institutional upper limit of normal unless this is a
             manifestation of GVHD

          -  Recurrent or progressive malignancy at any time after HCT, as applicable for the
             individual malignancy

          -  Subject was in any clinical study within the last 30 days

          -  Receipt of 5 or more prior agents to treat cGVHD

          -  Known hypersensitivity to alefacept or any components of the study medication

          -  Known to be positive for human immunodeficiency virus (HIV) antibodies

          -  Currently enrolled in any other study for chronic GVHD treatment and receiving
             treatment under the study or previous participation in this study.

          -  Pregnant or nursing

          -  Concurrent illness which, in the opinion of the Investigator, may interfere with
             treatment or evaluation of safety
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Corey Cutler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutch Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2010</study_first_submitted>
  <study_first_submitted_qc>October 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2010</study_first_posted>
  <results_first_submitted>January 28, 2013</results_first_submitted>
  <results_first_submitted_qc>August 11, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 13, 2013</results_first_posted>
  <last_update_submitted>August 11, 2013</last_update_submitted>
  <last_update_submitted_qc>August 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Corey S. Cutler, MD, MPH</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>GVHD</keyword>
  <keyword>Alefacept</keyword>
  <keyword>Amevive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alefacept</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Alefacept</title>
          <description>Alefacept administration (13 doses): Days 1 and 4 (subcutaneous), Weeks 1-12 (intravenous)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Alefacept</title>
          <description>Alefacept administration (13 doses): Days 1 and 4 (subcutaneous), Weeks 1-12 (intravenous)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Efficacy</title>
        <description>Proportion of patients with a favorable response, defined as a complete or partial remission at week 12 as compared to baseline in subjects with steroid refractory cGVHD.</description>
        <time_frame>2 years</time_frame>
        <population>All enrolled subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Alefacept</title>
            <description>Alefacept administration (13 doses): Days 1 and 4 (subcutaneous), Weeks 1-12 (intravenous)</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy</title>
          <description>Proportion of patients with a favorable response, defined as a complete or partial remission at week 12 as compared to baseline in subjects with steroid refractory cGVHD.</description>
          <population>All enrolled subjects</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety of Alefacept Infusions in Patients With Chronic GVHD.</title>
        <description>Assess the safety of alefacept in this patient population. The number of adverse events (including hematological and non-hematological safety events) will be used for safety assessment.</description>
        <time_frame>2 years</time_frame>
        <population>All enrolled subjects were included in the Analysis of Safety Events</population>
        <group_list>
          <group group_id="O1">
            <title>Alefacept</title>
            <description>Alefacept administration (13 doses): Days 1 and 4 (subcutaneous), Weeks 1-12 (intravenous)</description>
          </group>
        </group_list>
        <measure>
          <title>Safety of Alefacept Infusions in Patients With Chronic GVHD.</title>
          <description>Assess the safety of alefacept in this patient population. The number of adverse events (including hematological and non-hematological safety events) will be used for safety assessment.</description>
          <population>All enrolled subjects were included in the Analysis of Safety Events</population>
          <units>Total adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Alefacept</title>
          <description>Alefacept administration (13 doses): Days 1 and 4 (subcutaneous), Weeks 1-12 (intravenous)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection (otitis externa)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Corey S. Cutler, MD, MPH, FRCP(C)</name_or_title>
      <organization>Dana-Farber Cancer Institute</organization>
      <phone>617-632-5946</phone>
      <email>cscutler@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

